2023 San Antonio Breast Cancer Symposium (SABCS 2023)

Breast cancer survivors who are at least 50 years of age appear to do well with less frequent mammographic surveillance, with survival outcomes being no worse than with annual mammograms, according to data from the phase III Mammo-50 trial.

For postmenopausal women with genomically defined low-risk stage I breast cancer who have been initiated on endocrine therapy immediately after breast-conserving surgery, the risk of recurrence is low despite the omission of radiation therapy, as shown in the IDEA* trial.

The addition of capivasertib (C) to fulvestrant (F) results in better health-related quality of life (HRQoL), except for diarrhoea, in patients with aromatase inhibitor-resistant HR-positive/HER2-negative advanced breast cancer when compared to placebo plus F, according to the phase III CAPItello-291 study presented at SABCS 2023.

Body mass index (BMI) has some bearing on the efficacy of different adjuvant chemotherapy schedules in patients with early breast cancer, suggest the results of the GIM2 study, which were presented at the recent SABCS 2023. Additionally, dose-dense (DD) chemotherapy appears to be the better treatment strategy regardless of a patient’s BMI.

Coming on the heels of the second interim analysis, the protocol-specified final invasive disease-free survival (iDFS) analysis of the phase III NATALEE trial continues to show a highly significant iDFS benefit with the combination of the CDK 4/6 inhibitor ribociclib and a nonsteroidal aromatase inhibitor (NSAI) in individuals with HR+/HER2- early breast cancer.

In the final overall survival (OS) analysis of the phase III MONARCH 3 trial, the combination of the CDK 4/6 inhibitor abemaciclib and a nonsteroidal aromatase inhibitor (NSAI) continued to show clinically meaningful signals as first-line (1L) treatment for HR+/HER2- advanced breast cancer.